Dr Barbara Burtness speaks to ecancer at ASCO 2024 about the long-term follow up results of E3311, a phase II trial of transoral surgery followed by pathology-based adjuvant treatment in HPV-associated oropharynx cancer.

She explains that patients were randomised between a standard approach of 60Gy of post-operative radiation or a de-intensified approach of 50Gy.

Dr Burtness reports that this de-intensified approach lead to a 54 month progression-free survival of 90% and an overall survival of above 90%.